Gossamer Bio Slides as $250M Financing Hinges on FDA Milestones
Gossamer Bio Financing could provide up to $250 million, with much of the funding tied to seralutinib FDA milestones.
Read original at benzingaStocks · News reference
Gossamer Bio Restructures Debt, Secures Full Control of Lead Drug Candidate
Gossamer Bio plans a September 2026 NDA filing for seralutinib following FDA feedback and reacquires global rights.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 27, 2026, 6:11 PM
- Checked
- Jul 27, 2026, 6:11 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Gossamer Bio shares are trading higher after the company announced that it has entered into a securities purchase agreement for a private placement financing to provide up to $250 million in aggregate gross proceeds.
Read original at benzingaGossamer Bio Enters Into Securities Purchase Agreement For Up to $250M Structured Private Placement
– $150 Million of Committed Capital: $25 Million Funded Upfront at Initial Closing, Plus an Additional $125 Million that Funds Upon FDA Acceptance of the Seralutinib NDA in PAH –– Potential for Up to an Additional $100
Read original at benzinga8-K filing — Gossamer Bio, Inc. (GOSS)
Filed: 2026-08-21 AccNo: 0001728117-26-000077 Size: 1 MB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read original at edgar